Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Subscribe To Our Newsletter & Stay Updated
